Medicare in 2027: What’s Changing and What Pharmacies Should Expect at the Counter

Everyone's favorite time of year is almost here. Annual enrollment opens October 15, and your patients are going to walk in with questions.

The pattern across insurance lately has been pretty consistent: costs go up, coverage gets thinner. Medicare's no exception. For 2027, there are three numbers changing in Part D and one subsidy quietly going away, and all of it lands at your counter in January.

Here's what's actually changing, in plain terms.

Three numbers move

The deductible goes from $615 to $700. The out-of-pocket cap goes from $2,100 to $2,400.

The good part hasn't changed: once a patient hits that cap, covered drugs are $0 for the rest of the year. That's still the best thing about the redesigned benefit, and most patients don't know it exists.

The basic structure otherwise holds steady. The doughnut hole's been gone since 2025. The benefit still has three clean phases: deductible, initial coverage, and catastrophic. Covered insulin remains capped at no more than $35 for a month’s supply, and some products may cost less.

So the front of the year gets more expensive. The protection at the top is still there.

The subsidy nobody's talking about

For the past two years, CMS ran something called the Part D Premium Stabilization Demonstration. Plain version: it paid to keep standalone drug plan premiums from jumping. MedPAC estimates it reduced average PDP premiums by about $16 a month in 2026 and $26 a month in 2025. GAO has estimated the demonstration's cost at roughly $9.8 billion.

It ends December 31. CMS says plans have enough experience pricing the new benefit now to stand on their own, and Administrator Mehmet Oz has said most people will see increases under $10.

Two things come out of that. The demonstration's cap on year-over-year increases in individual standalone Part D plan premiums goes away in 2027. The separate 6% limit on growth of the national base beneficiary premium remains in place. And the plan-specific numbers aren't public yet. CMS set the 2027 base beneficiary premium at $41.33, up from $38.99, but that's a national benchmark, not what any individual patient necessarily pays. CMS expects the finalized 2027 plan-specific premium landscape in mid-to-late September.

Until then, if someone asks what their plan will cost next year, the honest answer is that their 2027 plan-specific premium hasn't been publicly released yet.

The timing conversation, especially for Extra Help patients

The $2,400 Part D out-of-pocket threshold works a little differently for patients receiving Extra Help.

Extra Help reduces what these patients personally pay for their prescriptions. But the low-income cost-sharing subsidy paid on their behalf still counts toward the Part D out-of-pocket threshold.

That means an Extra Help patient taking high-cost covered drugs may reach catastrophic coverage much earlier in the year even though their own out-of-pocket spending stays relatively low. Once they reach the threshold, covered Part D drugs have $0 cost sharing for the rest of the year.

The takeaway isn't to change when a patient fills a prescription just to reach the threshold sooner. It's to understand that high-cost therapy can move Extra Help patients through the benefit faster than their copays alone would suggest, and to help them understand what to expect over the course of the year.

The bigger squeeze

This isn't just a Part D story.

Costs in Original Medicare keep climbing, which can make Medicare Advantage attractive for people focused on lower upfront premiums and bundled benefits. But MA has pressures of its own. Some supplemental benefits have declined from their 2023 peaks, average in-network out-of-pocket limits increased in 2026, and plans continue to adjust where they offer coverage. Early signs suggest 2027 may bring less disruption than 2026, but the final plan landscape will determine what beneficiaries actually see.

The practical point is that premium alone doesn't tell the whole story. Patients still need to look at whether their doctors, drugs, pharmacy, and expected out-of-pocket costs line up with the plan.

A plan for October 15 to December 7

Before October 15. Get your technicians the three numbers: $700, $2,400, and $35 insulin, so the easy questions don't pull a pharmacist off the bench. Pull your list of patients on expensive therapy. They're the ones the deductible increase actually hits.

Mid-to-late September. Plan numbers publish. Before that, nobody can quote a 2027 premium, and it's fine to say so.

During AEP. Make sure your Extra Help patients understand how their reduced cost sharing interacts with the $2,400 out-of-pocket threshold, especially if they use high-cost medications.

January. Expect the walk-aways in the first two weeks. Staff for the conversation, not just the transaction.

Where this leaves patients

None of this is simple, and the changes are real. But it starts somewhere concrete: are this patient's doctors, drugs, and pharmacy actually covered? Answer that first and the rest is arithmetic. Get it wrong, and no premium savings makes up for it.

Plenty of pharmacies already help patients think this through, and they're well positioned to do it because they have visibility into the medications patients are actually taking. For pharmacies that don't want to handle plan comparisons themselves, a trusted broker can serve as an extension of the pharmacy, helping patients evaluate whether their doctors, drugs, and preferred pharmacy are covered before they make a decision.

Key takeaways

Deductible goes to $700, out-of-pocket cap to $2,400. Covered drugs are $0 after the cap. Doughnut hole still gone, insulin still $35.
The premium stabilization subsidy ends December 31, 2026, and with it goes the ceiling on how much a standalone plan can raise premiums year over year.
Plan-specific 2027 premiums aren't public until mid-to-late September. Anything quoted before then is a guess.
Extra Help dollars count toward the out-of-pocket cap. Filling expensive therapy earlier costs those patients nothing extra and gets them to $0 drugs sooner.
Costs are up and benefits thinner on both sides of the Medicare choice. Whether a patient's own doctors, drugs, and pharmacy are covered is the first question, not the premium.

Sources: